ER-Positive / HER2-Negative

This is the main hub for ER-positive, HER2-negative breast cancer on the site.

It focuses on endocrine therapy, resistance, dormancy, senescence, autophagy, and the questions that keep coming up around treatment timing, monitoring, and adjunctive support.

What this hub is tracking

In ER-positive, HER2-negative disease, treatment is rarely hitting just one kind of cell at a time.

At any given point there may be actively dividing cells, long-lived dormant cells, and therapy-induced senescent cells.

Standard ER-positive treatments can affect all three.

They kill some cells.

They also push some cells into survival states supported by autophagy and other stress-response pathways.

Autophagy is the cell’s self-recycling process.

It breaks down damaged parts, reuses them as fuel or building blocks, and helps the cell survive stress instead of dying.

This hub is built around a question that often gets missed in routine consults:

What happens to the cells that do not die under treatment pressure?

That question shapes how people think about off-label drugs, supplements, combinations, sequencing, timing, and monitoring.

Treatment timing and pressure

This section stays closest to standard treatment decisions in ER-positive, HER2-negative disease.

The emphasis is endocrine treatment pressure, CDK4/6 use, sequencing questions, and where trial findings may matter for timing.

• Endocrine therapy, resistance, and dormancy — section overview for endocrine treatment pressure, CDK4/6 use, dormancy, autophagy, senescence, ctDNA, and related resistance questions

• AI Resistance and the 4-OHE1/E2 Pathway — how estrogen metabolism, methylation, glutathione, elimination, and melatonin might matter in AI resistance

• CDK4/6 Options and Supplement Considerations — deep guide to palbociclib, ribociclib, abemaciclib, side effects, and supplement interaction questions

  • SONIA Trial and CDK4/6 Timing — what SONIA actually tested, and what it suggests about first-line versus later CDK4/6 use

  • Galectin‑3, Cyclin D1, Modified Citrus Pectin(MCP) and CDK4/6: A Patient Guide — how galectin-3, cyclin D1, MCP, and diet questions connect to the CDK4/6 pathway

• Fulvestrant and the Keto Diet — research notes on fulvestrant, metabolic context, and what is actually known about keto in this setting

Survival states and late escape

These pages focus on what standard ER-positive treatment pressure may leave behind.

The emphasis here is dormancy, therapy-induced senescence, autophagy-supported survival, slow-cycling survivors, and later escape routes.

• Dormancy, Senescence, Autophagy, and Trial Context in ER+ Disease — fuller walk-through of dormant cells, therapy-induced senescence, autophagy trials, and standard-treatment context

• Autophagy Escape in ER-Positive Breast Cancer — why autophagy, mTOR pressure, glycolysis, PI3K signalling, and HCQ keep surfacing in ER+ discussions

• Autophagy and Senescence in Antiestrogen Resistance — why endocrine therapy can hold disease quiet for years, and how late escape still happens

  • Overview and key takeaways — plain-language overview of why autophagy and reversible senescence matter in ER-positive antiestrogen resistance

  • Endocrine therapy, CDK4/6, and why resistance still happens — where standard ER-positive treatments help, and why cancers still find ways to survive

  • Autophagy — the first escape route — what autophagy is, how it works, and why it keeps surfacing here

  • Senescence — the second escape route — why treatment-induced senescence can protect surviving cells

  • Established resistance mechanisms — the main mutations and bypass pathways that may accumulate while cells survive

  • Glossary and trial notes — quick definitions and the current hydroxychloroquine-based trial landscape

• Endocrine Therapy, Stable Disease, and Dormancy in ER-Positive Breast Cancer — why endocrine therapy can hold disease quiet for long periods, and why late escape still happens

• Slow-Growing ER+ Breast Cancer Cells and How Rac-1 and The IGF Axis Supports Relapse — 2026 paper summary on slow-cycling, senescent-like ER+ survivors, Rac1 signalling, and the IGF-axis escape route

• New BCL‑2 Inhibitor Trial in HR+ MBC – and Why Whack-a-Mole Still Matters — why the new fulvestrant plus BCL-2 inhibitor trial matters, and where escape pressure may shift next

• ER-Positive, CDK4/6-Resistant, HER2-Mutant — why HER2-negative pathology and a later HER2 mutation are not the same thing

• FOX Family in ER+ Metastatic Breast Cancer — FOXA1 mutations, FOXM1 proliferation drivers, and the targeted-degradation question in ER-positive metastatic disease

When CDK4/6 inhibition fails to work.

Spotlight on Clinical trials - important information to know up-front

Capivasertib Intolerance and the Next-Generation PI3K/AKT Trials: What's Actually Open Right Now
A breakdown of which mutant-selective PI3K/AKT/mTOR trials currently accept patients who stopped capivasertib or a similar drug due to intolerance rather than progression, plus what's known about PIK3CA-mutation biology and supportive options to discuss with your oncologist.
ReDiscover-2 (NCT06982521)
This new drug (mentioned in the PIK/AKT trials page above) aims to shut down the specific PI3K‑alpha mutations feeding the cancer, but leave more of the normal PI3K‑alpha alone, so you keep the benefits of this pathway being targeted with fewer blood sugar, rash and digestive side effects than earlier medicines in this class. Read our trial overview page for RLY-2608 plus fulvestrant in PIK3CA-mutant HR-positive, HER2-negative advanced breast cancer.

Monitoring change early

This part of the hub gathers pages about detecting resistance or transition earlier, rather than only after clear clinical progression.

It keeps ctDNA, early ESR1 detection, and FGFR1 questions together.

• Blood Biopsy Trial — Getting Ahead of Treatment Resistance — how ctDNA and early ESR1 detection might support earlier, smarter treatment switching

• FGFR1 Amplification in ER+ Breast Cancer — plain-language guide to FGFR1 as an endocrine-resistance signal, including why a Guardant360 call can appear, fade, or disappear

Bone and metastasis context

When bone involvement or broader metastatic context becomes part of the picture, different pathways and support questions come forward.

This group keeps those pages together instead of scattering them through the main resistance material.

• Bone Metastases — an ever growing shared-topic hub covering bone-targeted therapy, integrative strategies, protocol notes, and community guidance

• FOXM1 in Bone Metastasis — why FOXM1 keeps surfacing in metastasis, bone biology, and the andrographolide story

• L.reuteri hits RANKL/Bone Axis — why L. reuteri is being discussed in ER-positive, HER2-negative disease with bone involvement

Practical and adjunct questions

Treatment metabolism and side-effect questions

• COMT Status and Tamoxifen — focused note on COMT-related interpretation questions for people on, or considering, tamoxifen

• Gilbert Syndrome, UGT1A1, and Estrogen Detox — notes on glucuronidation and estrogen-handling context

Receptor and subtype context

• ER+/PR- Receptor Status — what PR loss may signal in ER-positive disease and how it can shape thinking

• Distinguishing Luminal A from Luminal B — practical subtype guide to the main luminal categories

• AR+/ER+ Breast Cancer — deeper look at androgen-receptor-positive, estrogen-receptor-positive biology

• Androgen Modulation's Role in Healing Breast Cancer — background notes on androgen signalling beyond the AR+/ER+ page

Supplement and adjunct notes

• Ivermectin & ER+ Breast Cancer: What the 2026 Research Actually Found — focused note on the 2026 cell study, ESR1/ERα, HER2, pSMAD2, and tamoxifen synergy

• Melatonin, Palbociclib, and Cyclin D1 — focused preclinical note on melatonin in ER-positive disease when palbociclib drives compensatory cyclin D1 signalling

• Andrographis in ER-Positive Breast Cancer — focused note on ERα downregulation, fulvestrant synergy, resistance pressure, and bone-axis overlap

• Genistein Dosing in ER-Positive Breast Cancer — focused note on one of the most common soy-isoflavone questions in ER-positive disease

• Quercetin Notes on ER+ and Aromatase Modulation — dose dependency, COMT overlap, and aromatase questions

• Letrozole Side Effects and Possible Considerations — practical side-effect notes and things to watch for with one of the most used aromatase inhibitors

Community threads and shared docs

• Support Threads & Docs — Facebook study-support threads and shared docs that connect to broader breast-cancer and ER-positive questions

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form